VCAM1 and inflammatory bowel disease: Additionally, the pro-angiogenic effects of VCAM-1 activity—such as increased B-cell activation and cytokine signalling—stimulate vessel remodelling of the mucosal and submucosal microvascular architecture, which, in turn, exacerbates inflammatory cell recruitment and mucosal tissue destruction during IBD [58, 61].